SBIR/STTR Research Award
Efficient Synthesis of (+)-Discodermolide
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Kosan Biosciences, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The long term objective of this proposal
is to develop an efficient, economical means of producing the polyketide
(+)-discodermolide. This compound shows promising anticancer activity, having a
similar mode of action as paclitaxel and epothilone, but is available only in
minute quantity from its natural source, the deep-water marine sponge
Discodermia dissolute. Total synthesis is the only option at present for
producing sufficient quantities for clinical testing. Several total syntheses
have been reported, yet all are lengthly and expensive. The most concise
synthesis to date (Smith et al.) divides discodermolide into three segments.
Each segment is elaborated from a common precursor, itself prepared via a
multi-step route using expensive reagents. The PI proposes to develop a process
to prepare an equivalent of this common precursor by fermentation, using
genetically engineered polyketide synthases. In Phase 1, we will develop the
methods to prepare this material and demonstrate its utility by conversion to
the Smith common precursor. In Phase 2, we will develop the methodology to
incorporate our fermentation product directly into the synthesis of
(+)-discodermolide. The researchers will also explore the use of other natural
polyketides as more advanced synthetic intermediates to decrease the number of
steps required to produce discodermolide. The PI anticipates that this use of
engineered enzymes will dramatically reduce the cost of preparing
(+)-discodermolide, and facilitate the commercial development of this
anticancer agent.
PROPOSED COMMERCIAL APPLICATION:
Discodermolide is a potential successor to paclitaxel (Taxol). The current market for
paclitaxel is quite large, yet there are many problems associated with this drug.
Discodermolide has many favorable aspects, including greater water solubility and
activity against Taxol-resistance cells, and so could take over a large portion of the
Taxol market. The present proposal should overcome the supply problem of
discodermolide, thus facilitating it commercial development.
Technology keywords
Not reported